ArticleIrish journal of medical science2026
Efficacy of intradermal plus intramuscular Recombinant hepatitis B vaccination in vaccine nonresponders.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe aimed to determine the antibody response of intradermal (ID) plus intramuscular (IM) recombinant hepatitis B vaccination in individuals with inadequate immune response despite vaccination.
methodsThis single-center, retrospective study included individuals aged ≥18 years who had previously completed the primary 3-dose vaccination course for hepatitis B and had anti-HBs titers <10 mlU/ml. Participants were administered a double dose of recombinant hepatitis B vaccine (5 microgram ID+35 microgram IM) at months 0, 1, and 6. Quantitative anti-HBs titers were assessed at months 2 and 7. Vaccination response was categorized as unresponsive (anti-HBs<10 mlU/ml), weak (anti-HBs=10-100 mlU/ml), moderate (anti-HBs=101-1000 mlU/ml), and strong (anti-HBs>1000 mlU/ml).
resultsA total of 43 individuals were included. After the 2nd and 3rd doses of vaccination, protective antibody responses (anti-HBs>10 mlU/ml) were obtained 81.3% (27.9% weak response, 16.3% moderate response, 37.2% strong response) and 93% (16.3% weak response, 27.9% moderate response, 48.8% strong response), respectively. Anti-HBs antibody titers increased from 505±501 in the 2nd vaccination to 666±469 in the 3rd vaccination (p=0.003). After the 3rd dose of vaccination, protective antibody responses inreased from 86.7% to 100% in PLwHIV, from 69.2% to 76.9% in patients with rheumatic diseases, and from 91.7% to 100% in immunocompetent individuals compared to the second dose of vaccination. No antibody response was achieved in any of the patients using rituximab.
conclusionID (5 µg) plus IM (35 µg) recombinant hepatitis B vaccine is promising as an alternative vaccination method in various specific populations, which unresponsive to standard vaccination, such as PLwHIV, immunocompetent patients, and immunomodulator users.
Indexed as
Identifiers
41182584What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.